However, combination treatment with tier 1 neoantigen and anti-PD-1 significantly reduced tumor growth (tier 1: p = 0.019), whereas combined treatment with nontier 1 neoantigen and anti-PD-1 was not equally effective (nontier 1: p = 0.986). The gene discussed is PDCD1; the disease is neoplasm.